Follow-up of the Cardiomyopathy Cohort SFB/TR19
Launched by UNIVERSITY MEDICINE GREIFSWALD · Nov 19, 2016
Trial Information
Current as of May 12, 2025
Recruiting
Keywords
ClinConnect Summary
The "Follow-up of the Cardiomyopathy Cohort SFB/TR19" clinical trial is studying patients who have inflammatory cardiomyopathy, a condition that affects the heart muscle and can lead to heart failure. This trial is looking to gather more information about these patients to better understand their health over time. If you or a family member participated in the initial SFB/TR19 study, you might be eligible to join this follow-up.
Participants can expect to undergo a thorough review of their medical history, physical exams, and tests to check for certain health markers. Additionally, samples may be collected for research purposes to help scientists learn more about this condition. The trial is open to all adults aged 65 to 74, and there are no specific exclusions, so if you qualify based on the previous study, your participation is welcomed. This research could help improve care for people with similar heart conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participation in baseline examination of SFB/TR19
- Exclusion Criteria:
- • none
About University Medicine Greifswald
University Medicine Greifswald is a prominent academic medical center located in Greifswald, Germany, dedicated to advancing healthcare through innovative research and clinical excellence. As a clinical trial sponsor, it fosters a collaborative environment that integrates cutting-edge scientific inquiry with patient care, focusing on a wide range of medical disciplines. The institution is committed to enhancing patient outcomes by conducting rigorous clinical trials that adhere to the highest ethical standards and regulatory requirements. With a strong emphasis on interdisciplinary collaboration, University Medicine Greifswald aims to contribute significantly to the development of new therapies and medical advancements, ultimately improving healthcare delivery and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Greifswald, Mv, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials